BRCA1 and neoplasm: Preclinical data demonstrated that inhibition of BET protein BRD4 resulted in a homologous repair-deficient phenotype, which was associated with PARPi sensitivity in vitro and in vivo regardless of BRCA1/2 or RAS/RAF status, suggesting that the combination could have activity outside of HRD-positive tumours.